# OGN catalysts: Organon & Co. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ogn/catalysts

> Organon & Co. (OGN) has 2 upcoming catalysts. The next is the tapinarof cream, 1% primary completion, August 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Organon & Co. |
| Ticker | OGN (NYSE) |
| SEC CIK | 1821825 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ogn |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 15, 2002 | [Exxua (gepirone hydrochloride) complete response letter (CRL)](https://sec-api.dev/pdufa/gepirone) | OGN |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 03/15/2002 for NDA 021164 to Organon, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22021164Orig1s000OtherActionLtrs.pdf%22)) |
| June 23, 2004 | [Exxua (gepirone hydrochloride) complete response letter (CRL)](https://sec-api.dev/pdufa/gepirone) | OGN |  | completed, complete response letter | "COMPLETE RESPONSE letter dated 06/23/2004 for NDA 021164 to Organon, Inc.." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22021164Orig1s000OtherActionLtrs.pdf%22)) |
| December 7, 2021 | [Clindamycin Phosphate In 0.9% Sodium Chloride (clindamycin phosphate) FDA approval](https://sec-api.dev/pdufa/clindamycin) | OGN |  | completed, approved | "NDA215650 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20211207, review_priority PRIORITY; sponsor_name ORGANON LLC; product XACIATO (CLINDAMYCIN PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215650%22)) |
| May 23, 2022 | [Vtama (tapinarof) FDA approval](https://sec-api.dev/pdufa/tapinarof) | OGN | To treat plaque psoriasis | completed, approved | "Vtama \| tapinarof \| 5/23/2022 \| To treat plaque psoriasisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| December 12, 2024 | [Vtama (tapinarof) label expansion decision](https://sec-api.dev/pdufa/tapinarof) | OGN |  | completed, approved | "NDA215272 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20241212, review_priority STANDARD; sponsor_name ORGANON LLC; product VTAMA (TAPINAROF)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215272%22)) |
| February 13, 2025 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925012546/tm256470d1_ex99-1.htm)) |
| May 1, 2025 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the First Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925043023/tm2513730d1_ex99-1.htm)) |
| May 28, 2025 | [OG-6219 primary completion](https://sec-api.dev/pdufa/og-6219) | OGN | Endometriosis | completed | "NCT05560646 (A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Organon and Co; Results First Posted 2026-05-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05560646)) |
| August 5, 2025 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the Second Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925073929/tm2522571d1_ex99-1.htm)) |
| Sep 2025 | [Prolia® (denosumab) FDA approval](https://sec-api.dev/pdufa/denosumab) | OGN |  | completed, approved | "To a lesser extent, during the third quarter the Biosimilars portfolio also benefitted from contribution from new assets; Bildyos® (denosumab-nxxp) and Bilprevda® (denosumab-nxxp), which was approved by the FDA in September 2025, and Tofidence® (tocilizumab-bavi), which the company acquired in the second quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/tm2530711d1_ex99-1.htm)) |
| November 10, 2025 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the Third Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/tm2530711d1_ex99-1.htm)) |
| January 16, 2026 | [Implanon (etonogestrel) label expansion decision](https://sec-api.dev/pdufa/etonogestrel) | OGN |  | completed, approved | "NDA021529 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260116, review_priority STANDARD; sponsor_name ORGANON; product IMPLANON (ETONOGESTREL)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021529%22)) |
| February 12, 2026 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465926013888/tm266144d1_ex99-1.htm)) |
| February 19, 2026 | [Miudella (miudella) FDA approval](https://sec-api.dev/pdufa/miudella) | OGN |  | completed, approved | "On February 19, 2026, we entered into an exclusive license agreement with Sebela for the global rights to Miudella®, a hormone-free copper intrauterine device ("IUD") that was approved by the FDA on February 24, 2025 and is estimated to launch commercials sales in the United States in late 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1821825/000162828026051230/ogn-20260630.htm)) |
| April 30, 2026 | [Organon & Co. earnings report](https://sec-api.dev/companies/ogn/catalysts) | OGN |  | completed | "Organon Reports Results for the First Quarter" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/tm2613165d1_ex99-1.htm)) |
| May 8, 2026 | [OG-6219 topline data readout](https://sec-api.dev/pdufa/og-6219) | OGN | Endometriosis | completed | "NCT05560646 (A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Organon and Co; Results First Posted 2026-05-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05560646?tab=results)) |
| October 14, 2026 | [Tapinarof cream, 1% primary completion](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Plaque Psoriasis | completed | "NCT05172726 (Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-14 (ACTUAL); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172726)) |
| Oct 2026 to Jan 2027 | [Tapinarof cream, 1% topline data readout](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Plaque Psoriasis | scheduled | "NCT05172726 (Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-14 (ACTUAL); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172726)) |
| August 2027 | [Tapinarof cream, 1% primary completion](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Atopic Dermatitis | scheduled | "NCT07265479 (A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07265479)) |
| Aug to Nov 2027 | [Tapinarof cream, 1% topline data readout](https://sec-api.dev/pdufa/tapinarof-cream-1) | OGN | Atopic Dermatitis | scheduled | "NCT07265479 (A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Organon and Co." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07265479)) |

## Drugs

- [Implanon (etonogestrel)](https://sec-api.dev/pdufa/etonogestrel): 
- [Exxua (gepirone hydrochloride)](https://sec-api.dev/pdufa/gepirone): 
- [Miudella (miudella)](https://sec-api.dev/pdufa/miudella): 
- [OG-6219](https://sec-api.dev/pdufa/og-6219): Endometriosis
- [Vtama (tapinarof)](https://sec-api.dev/pdufa/tapinarof): To treat plaque psoriasis
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1): Plaque Psoriasis, Atopic Dermatitis, Plaque Type Psorisis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ogn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "OGN catalysts: Organon & Co. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ogn/catalysts

```bibtex
@misc{secapidev_companies_ogn_catalysts_20261116,
  title        = {OGN catalysts: Organon & Co. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ogn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ogn_catalysts_20261116","title":"OGN catalysts: Organon & Co. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ogn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
